FOI release

Freedom of Information request on Pre-school Booster vaccine Repevax

Published 28 May 2021

27th April 2021 FOI 21/338

Dear

Thank you for your email dated 7 th April 2021, where you asked for information on the following:

Please can you send me what has been reported on this scheme for the Pre-school Booster vaccine Repevax by Sanofi Pasteur.

Further to your request, I am pleased to be able to provide you with a Product Analysis Print (PAP) which lists all UK spontaneous suspected Adverse Reaction (ADR) reports associated with the Repevax vaccine product, used in the UK, up to the 11th April 2021. As of this date, the MHRA has a total of 952 Yellow Card reports in association with Repevax. Repevax is currently on the routine immunisation schedule for both children aged three years four months old as well as pregnant women. Please note that as your request specified the indication as the pre-school booster, reports pertaining to vaccine exposure during pregnancy have been excluded from the data provided. Please also find attached a guidance sheet which provides you with further information on how to interpret the print.

When considering the attached spontaneous data, it is important to be aware of the following points: • A reported reaction does not necessarily mean it has been caused by the vaccine, only that the reporter had a suspicion it may have. Each year, millions of doses of routine vaccinations are given in the UK alone, and when any vaccine is administered to large numbers of people, some recipients will inevitably experience illness following vaccination. The fact that symptoms occur after use of a vaccine or medicine, and are reported via the Yellow Card Scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental. • It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular medicine, and may be stimulated by promotion and publicity about a drug. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time.

The MHRA continuously monitors the safety of vaccines through a variety of pharmacovigilance processes including the Yellow Card Scheme. As part of our signal detection processes all adverse reaction reports received by the Yellow Card Scheme are individually assessed and cumulative information reviewed at regular intervals. If appropriate, regulatory action would be taken if any serious risks were confirmed.

As these data do not necessarily refer to proven side effects, you should refer to the product information which can be found here: https://products.mhra.gov.uk/ for details on the recognised possible side effects of each vaccine.

I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely, FOI Team, Vigilance and Risk Management of Medicines Division